ArticleCureus2025
Progesterone Modulates Placental Expression of p53 and β-Catenin in a Zone-Specific Manner in Dexamethasone-Treated Rats.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction The placenta is a transient pregnancy organ, and its development depends on proliferation and apoptosis throughout pregnancy. Abnormal placental development can result in intrauterine growth restriction (IUGR). Progesterone has a major role in regulating cell death and survival in various tissues, and its low maternal levels are highly correlated with IUGR. Aim The aim of this article was to evaluate the modulatory effect of progesterone on placental cell death and survival in a rat model of dexamethasone-induced IUGR. Methods Pregnant Sprague-Dawley rats were treated with a daily intraperitoneal (i.p.) injection: control (saline), dexamethasone, dexamethasone and progesterone, and progesterone. Injections started from 15 days of gestation (dg) until the end of the experiment at 21 days of gestation. The fetus and the placenta were weighed, and the placental labyrinth and basal zones were weighed and taken for gene and protein analysis of p53 and β-catenin. Key results Dexamethasone treatment resulted in decreased maternal progesterone levels, and fetal body and placental basal and labyrinth zone weights. Dexamethasone treatment significantly increased p53 expression in the basal and labyrinth zones and decreased β-catenin expression in the basal zone only. Progesterone co-supplementation with dexamethasone alleviated the increase in p53 levels in the labyrinth zone only and restored the expression of β-catenin in the basal zone. Conclusion Despite progesterone modulation of cell survival and growth, the effect was not translated into improved fetal or placental weights. Implication: These results highlight the importance of the zone-specific effect of progesterone in modulating cell death and survival in the placental complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.